首页>投融资
佐力药业
增发
Zhejiang Jolly Pharmaceutical Co Ltd, established in 1995 and listed on Shenzhen Stock Exchange in 2011, mainly focuses on R&D, production and sale of traditional Chinese Medicines, including Wuling powder, tablets, capsules, granules and freeze-dried powders.In September 2014, Zhejiang Jolly Pharmaceutical signed an investment agreement with the former shareholders of Zhejiang Kaixin Medicine to acquire 47.5% stock right of Kaixin Medicine for RMB 12 million (US $1.95 million) and simultaneously use cash for a capital increase. The price of the capital increase was to be RMB 1 (US $0.16) capital contribution to RMB 2.4 (US $0.39) and the amount of capital increment would be RMB 12 million (US $1.95 million). After completion of the transaction, Jolly Pharmaceutical would hold 65% of Kaixin Medcine. The acquisition and capital increase was expected to be RMB 24 million (US $3.90 million) in total.In June 2014, Zhejiang Jolly Pharmaceutical announced that trading of its shares was suspended from
基本信息
-
公司全称浙江佐力药业股份有限公司
-
类型中药产品生产商
-
产业领域药品研发/制造、医药研发/制造、化学药、中药
-
公司人数
-
地址浙江省德清县阜溪街道志远北路388号
-
联系电话
-
邮箱
-
成立时间2000-01-28
投融资
-
2022-12-13增发9.1亿人民币华夏基金诺德基金财通基金江山投资优优财富投资大成基金沣途资本上海盘京投资瑞银
-
2019-03-04未透露1.4亿人民币未透露
-
2018-09-18未透露1.2亿人民币未透露
-
2015-07-10战略融资未透露江苏瑞华长城国融投资
-
2015-07-09增发8026.6万人民币中国长城资产瑞华控股中汇会计师事务所有限公司东方华银国金证券
-
2011-02-22IPO47000万人民币未透露
-
2011-02-22上市4.7亿人民币未透露
- 加载更多
相关投融资企业
未公开
贵阳新天药业股份有限公司创建于1995年8月，2017年5月19日在深圳证券交易所中小企业板上市交易，股票简称：新天药业，股票代码：002873。公司属于医药制造业的中成药生产行业，拥有通过GMP认证的硬胶囊剂、合剂、颗粒剂、凝胶剂、片剂、糖浆剂、酒剂、露剂等八个剂型生产线及中药饮片A线、B线两条饮片生产线。主要从事泌尿系统疾病类、妇科类及其他病因复杂类疾病用药的中成药产品研究开发、生产与销售，为患者提供安全、有效的产品。
增发
Zhejiang Jolly Pharmaceutical Co Ltd, established in 1995 and listed on Shenzhen Stock Exchange in 2011, mainly focuses on R&D, production and sale of traditional Chinese Medicines, including Wuling powder, tablets, capsules, granules and freeze-dried powders.In September 2014, Zhejiang Jolly Pharmaceutical signed an investment agreement with the former shareholders of Zhejiang Kaixin Medicine to acquire 47.5% stock right of Kaixin Medicine for RMB 12 million (US $1.95 million) and simultaneously use cash for a capital increase. The price of the capital increase was to be RMB 1 (US $0.16) capital contribution to RMB 2.4 (US $0.39) and the amount of capital increment would be RMB 12 million (US $1.95 million). After completion of the transaction, Jolly Pharmaceutical would hold 65% of Kaixin Medcine. The acquisition and capital increase was expected to be RMB 24 million (US $3.90 million) in total.In June 2014, Zhejiang Jolly Pharmaceutical announced that trading of its shares was suspended from
未公开
贵阳新天药业股份有限公司创建于1995年8月，2017年5月19日在深圳证券交易所中小企业板上市交易，股票简称：新天药业，股票代码：002873。公司属于医药制造业的中成药生产行业，拥有通过GMP认证的硬胶囊剂、合剂、颗粒剂、凝胶剂、片剂、糖浆剂、酒剂、露剂等八个剂型生产线及中药饮片A线、B线两条饮片生产线。主要从事泌尿系统疾病类、妇科类及其他病因复杂类疾病用药的中成药产品研究开发、生产与销售，为患者提供安全、有效的产品。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息